TickerGraveyard
TickerGraveyard

XNCR

Delisted
Telesis Bio Inc.

XNCR — Post-Mortem

Telesis Bio Inc. entered the biotechnology sector focused on advancing synthetic biology. Established in 2019, it completed its initial public offering in January 2021 under the ticker symbol TBIO, raising $25 million. The company initially experienced growth driven by rising demand for genomic tools but struggled as market conditions deteriorated. By November 2024, Telesis Bio faced significant liquidity issues, culminating in its entry into promissory notes worth $3 million to alleviate cash flow problems. These notes, which carried a high interest rate of 12%, were indicative of the company's financial strain. The reliance on debt further raised concerns among investors, triggering compliance issues with Nasdaq's minimum listing standards. Ultimately, the cumulative effect of these misf

Telesis Bio Inc. (XNCR) faced delisting after failing to comply with Nasdaq listing requirements, highlighted by escalating financial instability and reliance on high-interest debt.

Could I Have Seen This Coming?

No structured pre-delisting signals found in our records. Absence of signals does not imply absence of risk.

Post-Mortem Analysis

Five-section narrative grounded in primary filings and contemporaneous reporting.

Origin

Telesis Bio was founded in 2019, focusing on synthetic biology solutions.

Peak

The company's peak occurred shortly after its IPO in January 2021, with strong initial investor interest and market potential.

Turning Point

In late 2024, Telesis Bio's reliance on high-interest debt highlighted its financial distress, marked by the issuance of promissory notes totaling $3 million on November 4, 2024.

End

The company faced delisting as it failed to meet Nasdaq's compliance requirements following mounting financial instability.

Impact

The company's failure serves as a cautionary tale regarding the risks of high-leverage financial strategies in volatile markets.

Lessons for Today's Investors

Transferable patterns identified from this case, written as research-report observations.

  1. 1

    Companies should maintain adequate liquidity to avoid dependence on high-interest debt instruments, especially in volatile markets.

  2. 2

    Understanding compliance requirements and maintaining listing standards is crucial for NASDAQ companies to avoid delisting ramifications.

  3. 3

    Investors should critically assess the implications of high-interest financing on a company's long-term viability.

Frequently Asked Questions

What was Telesis Bio Inc. focused on?
Telesis Bio Inc. was primarily focused on synthetic biology solutions and was publicly listed under the ticker TBIO.
What financial measures did Telesis Bio take before delisting?
The promissory notes entered on November 4, 2024, totaled $3 million with a 12% annual interest rate, maturing on January 15, 2026.
Why did Telesis Bio Inc. face delisting?
Due to financial instability and inability to meet compliance requirements, Telesis Bio faced delisting from Nasdaq.

Source Filings

Every fact on this page is anchored to a primary SEC filing or regulatory record. Open any source to verify against the original document.

Narrative sections on this page are AI-assisted summaries of the filings linked above. All content is reviewed against primary sources; if you find an error, the canonical record is always the linked filing.

Industries:

Tags:

Related tickers:

Share: